Previous 10 | Next 10 |
Earnings season seems to be the pill needed to improve sentiment on Vanda Pharmaceuticals (NASDAQ: VNDA) . The commercial-stage biotech saw its share price rise by almost 1% on Thursday, following the release of quarterly results that comfortably topped analyst estimates. By contrast, the...
Vanda Pharmaceuticals Inc. (VNDA) Q4 2022 Earnings Conference Call February 08, 2023, 04:30 AM ET Company Participants Kevin Moran - CFO Mihael Polymeropoulos - President, CEO and Chairman Timothy Williams - General Counsel Conference Call Participants Pr...
Vanda Pharmaceuticals press release ( NASDAQ: VNDA ): Q4 GAAP EPS of $0.12 beats by $0.04 . Revenue of $64.5M (-5.2% Y/Y) misses by $3.1M . 2023 Financial Guidance Given uncertainties surrounding the U.S. market for HETLIOZ ® for the treatment of Non-24 as...
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results PR Newswire Q4 2022 total revenues were $64.5 million Full year 2022 revenues were $254.4 million Vanda provides update on pipeline advancements and upcoming milestones ...
Vanda Pharmaceuticals ( NASDAQ: VNDA ) is scheduled to announce Q4 earnings results on Wednesday, February 8th, after market close. The consensus EPS Estimate is $0.08 and the consensus Revenue Estimate is $67.6M (-0.6% Y/Y). For further details see: Vanda Pharmaceutical...
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 8, 2023 PR Newswire Conference Call and Webcast to Follow WASHINGTON , Feb. 1, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today a...
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference PR Newswire WASHINGTON , Jan. 6, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the J.P. Morgan Hea...
Generic versions of Vanda Pharmaceuticals' ( NASDAQ: VNDA ) (tasimelteon) could soon hit the market after a federal appeals court judge lifted a temporary injunction. The United States Court of Appeals for the Federal Circuit granted that injunction earlier in December . Teva Phar...
Fanapt® Shown to be Effective in Bipolar I Disorder in Phase III Clinical Study PR Newswire Supplemental New Drug Application (sNDA) planned for 2023 WASHINGTON , Dec. 19, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) tod...
Vanda Pharmaceuticals Provides an Update to HETLIOZ® ANDA Litigation Appeal: Federal Circuit grants motion to temporarily enjoin generic launch PR Newswire WASHINGTON , Dec. 16, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) toda...
News, Short Squeeze, Breakout and More Instantly...
Vanda Pharmaceuticals Inc. Company Name:
VNDA Stock Symbol:
NASDAQ Market:
Vanda Pharmaceuticals Inc. Website:
2024-07-17 04:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-11 07:00:07 ET Charles Duncan from Cantor Fitzgerald issued a price target of $11.00 for VNDA on 2024-07-11 06:12:00. The adjusted price target was set to $11.00. At the time of the announcement, VNDA was trading at $5.21. VNDA currently trades -22.96% versus its...
Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex PR Newswire WASHINGTON , July 1, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. District Court for the District of ...